Corvus Pharmaceuticals (CRVS) Non-Current Assets (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Non-Current Assets of $798000.0 for Q1 2026, down 34.0% year-over-year from $1.2 million in Q1 2025, and down 11.73% quarter-over-quarter from $904000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Non-Current Assets (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $798000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 34.0% year-over-year to $798000.0; the TTM figure through Mar 2026 stood at $798000.0 (down 34.0% YoY), while the FY2025 annual figure was $904000.0, down 31.31% from the prior year.
- Non-Current Assets for Q1 2026 stood at $798000.0, down from $904000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $36.9 million in Q1 2022, with the low at $798000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $1.3 million (2023), against an average of $8.1 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets sank 95.74% in 2023, then gained 0.98% in 2024.
- Corvus Pharmaceuticals' Non-Current Assets stood at $1.7 million in 2022, then declined by 13.62% to $1.4 million in 2023, then decreased by 7.78% to $1.3 million in 2024, then slumped by 31.31% to $904000.0 in 2025, then decreased by 11.73% to $798000.0 in 2026.
- Business Quant data shows CRVS's Non-Current Assets at $798000.0 in Q1 2026, $904000.0 in Q4 2025, and $1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 695,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 695,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | 904,000.00 |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 1.43 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.44 Mn |
| Mar 31, 2023 | 22.65 Mn |
| Dec 31, 2022 | 1.65 Mn |
| Sep 30, 2022 | 29.08 Mn |
| Jun 30, 2022 | 33.66 Mn |
| Mar 31, 2022 | 36.92 Mn |
| Dec 31, 2021 | 38.14 Mn |
| Sep 30, 2021 | 40.57 Mn |